What should you assess for schizophrenia?

Schizophrenia is a chronic, or lifelong, brain disorder that interferes with a person’s thoughts, feelings, and behaviors. People with schizophrenia may have hallucinations, delusional or distorted thoughts, or feelings of paranoia. 

Hearing voices is the most common type of hallucination among people with schizophrenia. They may hear these voices talking directly to them about their behavior, ordering them to do things, or warning them of danger. They may also hear these voices talking to each other. People with schizophrenia may hear voices for a long time before their family and friends notice a change in their behavior.

They also may have have firmly held beliefs that others find irrational. These delusions may include paranoid beliefs that others intend to harm them, or are spying on them, or are reading their mind. These delusions can involve a wide range of beliefs that others in the same cultural community find to be strange and contrary to their experience.

Symptoms of Schizophrenia

Schizophrenia is a common form of psychosis, a medical condition that skews the way a person perceives reality. A sudden change in personality and behavior, which occurs when a person with schizophrenia mentally “disconnects” from reality—when they can’t tell what is real from what is imagined—is called a psychotic episode. Hallucinations and delusions are part of psychosis, and people with schizophrenia often experience psychotic episodes.

Psychosis can have many causes, and the process of diagnosis often involves ruling out other conditions that can produce similar symptoms, such as substance use, depression, or bipolar disorder. Symptoms of schizophrenia can vary and even change over time. 

People with schizophrenia may have poor interpersonal skills. They are sometimes unable to show emotion and may have difficulty initiating a conversation or participating in other activities. Personal hygiene may deteriorate, and some people experience a decline in cognitive functioning, including difficulty with attention, memory, the speed of mental processing, and problem solving.

The condition affects men and women equally. It most often appears in men in their late teens or early 20s and in women in their late 20s or early 30s. Schizophrenia occurs in about 1 percent of the general population and in 10 percent of people who have a first-degree relative with the disorder, such as a parent or sibling. People who have second-degree relatives with schizophrenia, such as aunts, uncles, or grandparents, also develop the condition more often than the general population.

Causes of Schizophrenia

The exact cause of schizophrenia is not known, but scientists believe a combination of genetics and environmental factors—such as exposure to viruses while in the womb, or complications during birth, such as a baby deprived of an adequate supply of oxygen—may play a role. Imbalances in certain chemical messengers in the brain, called neurotransmitters, may also contribute to schizophrenia. Neurotransmitters transmit messages between nerve cells and the body’s muscles and organs. They play a role in mood, attentiveness, anger, learning, and memory.

Diagnostic Process

The illness often follows a progression, starting with a prodromal stage, in which the person exhibits a decline in functioning and may display very mild forms of psychosis, such as odd beliefs or unusual perceptional experiences. A diagnosis is not made until more clear-cut symptoms of psychosis emerge and only after a very careful review of all other possible causes. Our specialists are experts in this process. 

To make a diagnosis, a doctor performs a physical exam and conducts a thorough review of a person’s medical, psychiatric, and family history. The doctor may ask the person to describe any distressing experiences and perceptions. In addition, he or she asks about any concerns the person may have about achieving life goals as a result of new difficulties with motivation or cognition. Safety is also carefully assessed.

To receive a diagnosis of schizophrenia, a person must have experienced at least two of the following symptoms most of the time during a one-month period, with some level of disturbance being present for six months: 

• delusions, such as a belief that a person is being poisoned
• hallucinations, such as hearing a voice that issues orders
• disorganized speech, such as logic that is difficult for others to understand
• catatonic behavior, ranging from coma-like inactivity to hyperactivity
• reduced ability to function, such as neglecting basic hygiene

At least one of the symptoms must be delusions, hallucinations, or disorganized speech.

In determining a diagnosis, the doctor may order additional tests, including an MRI scan or blood test. 

MRI Scan

An MRI scan—in which magnetic fields and sound waves are used to create two- or three-dimensional images—may provide a good view of the structure of the brain and rule out schizophrenia by detecting abnormalities that may be causing schizophrenia-like symptoms.

Blood Test

A routine blood test can help a doctor rule out conditions with similar symptoms, such as alcohol and drug abuse. Interactions between certain medications, such as corticosteroids and cardiovascular medications, can also cause schizophrenia-like symptoms.

At the end of an evaluation for schizophrenia, the doctor shares the diagnostic results with the person and his or her family. They then decide if they’d like to schedule a consultation appointment with an NYU Langone specialist to discuss treatment, which often includes a combination of medication and psychosocial therapy.

1. Crow TJ. Molecular pathology of schizophrenia: More than one disease process? Br Med J. 1980;280:66–68. [PMC free article] [PubMed] [Google Scholar]

2. Andresen NC, Flaum M, Arndt S, Alliger R, Swayze VW. Positive and negative symptoms: Assessment and validity. Negative vs Positive Schizophrenia. 1991:28–51. [Google Scholar]

3. Crow TJ. The two-syndrome concept: Origins and current status. Schizophr Bull. 1985;11:471–486. [PubMed] [Google Scholar]

4. Andresen NC. The scale for the assessment of positive symptoms. Iowa City: University of Iowa Press; 1984. [Google Scholar]

5. Andresen NC. The scale for the assessment of positive symptoms. Iowa City: University of Iowa Press; 1985. [Google Scholar]

6. Andresen NC, Flaum M, Arndt S, Alliger R, Swayze VW. Positive and negative symptoms: Assessment and validity. Negative versus positive schizophrenia. 1992:28–51. [Google Scholar]

7. Johnstone EC, Owens DGC, Firth CD, Crow TJ. The relative stability of positive and negative features in chronic schizophrenia. Br J Psychiatry. 1986;150:60–64. [PubMed] [Google Scholar]

8. Malia AK, Norman RM, Williamson P. Stability of positive and negative symptoms in schizophrenia. Can J Psychiatry. 1993;38:617–621. [PubMed] [Google Scholar]

9. Klimidis S, Stuart GW, Minas IH, Copolov DL, Singh BS. Positive and negative symptoms in the psychoses. Re-analysis of published SAPS and SANS global ratings. Schizophr Res. 1993;9:11–18. [PubMed] [Google Scholar]

10. Minas IH, Stuart GW, Klimidis S, Jackson HJ, Singh BS, et al. Positive and negative symptoms in the psychoses: Multidimensional scaling of SAPS and SANS items. Schizophr Res. 1992;8:143–156. [PubMed] [Google Scholar]

11. Andreasen NC, Arndt S, Miller D, Flaum M, Nopoulos P. Correlational studies of the scale for the assessment of negative symptoms and the scale for the Assessment of positive symptoms: An overview and update. Psychopathology. 1995;28:7–17. [PubMed] [Google Scholar]

12. Rabinowitz J, Harvey PD, Eerdekens M, Davidson M. Premorbid functioning and treatment response in recent-onset schizophrenia. Br J Psychiatry. 2006;189:31–35. [PubMed] [Google Scholar]

13. Mortimer AM. Symptom rating scales and outcome in schizophrenia. Br J Psychiatry Suppl. 2007;50:S7–S14. [PubMed] [Google Scholar]

14. Obermeier M, Schennach-Wolff R, Meyer S, Möller HJ, Riedel M, et al. Is the PANSS used correctly? A systematic review. BMC Psychiatry. 2011;11:113. [PMC free article] [PubMed] [Google Scholar]

15. Alphs LD, Summerfelt A, Lann H, Muller RJ. The negative symptom assessment: A new instrument to assess negative symptoms of schizophrenia. Psychopharmacol Bull. 1989;25:159–163. [PubMed] [Google Scholar]

16. Axelrod BN, Goldman RS, Alphs LD. Validation of the 16-item negative symptom assessment. J Psychiatr Res. 1993;27:253–258. [PubMed] [Google Scholar]

17. Velligan DI, Alphs L, Lancaster S, Morlock R, Mintz J. Association between changes on the negative symptom assessment scale (NSA-16) and measures of functional outcome in schizophrenia. Psychiatry Res. 2009;169:97–100. [PubMed] [Google Scholar]

18. Kane JM. Tools to assess negative symptoms in schizophrenia 2013 [PubMed] [Google Scholar]

19. Portilla MPG, Alvarez LG, Saiz PA. Psychometric evaluation of the negative syndrome of schizophrenia. Eur Arch Psychiatry Clin Neurosci. 2015;265:559–566. [PubMed] [Google Scholar]

20. Alphs L, Morlock R, Coon C, Cazorl P, Szegedi A, et al. Validation of a 4-item negative symptom assessment (NSA-4): A short, practical clinical tool for the assessment of negative symptoms in schizophrenia. Int J Methods Psychiatr Res 2011 [PMC free article] [PubMed] [Google Scholar]

21. Haro JM, Kamath SA, Ochoa S. The clinical global impression-schizophrenia scale: A simple instrument to measure the diversity of symptoms present in schizophrenia. Acta Psychiatr Scand Suppl. 2003:16–23. [PubMed] [Google Scholar]

22. Guy W. Clinical global impression In: ECDEU assessment manual for psychopharmacology (revised) Rockville, MD: National institute of mental health; 1976. pp. 217–221. [Google Scholar]

23. Spearing MK, Post RM, Leverich GS, Brandt D, Nolen W. Modification of the clinical global impressions (CGI) scale for use in bipolar illness (BP): The CGI-BP. Psychiatry Res. 1997;73:159–171. [PubMed] [Google Scholar]

24. Haro JM, Edgell ET, Jones PB, Alonso J, Gavart S. The European schizophrenia outpatient health outcome (SOHO) study: Rationale, methods and recruitment. Acta Psychiatr Scand. 2003;107:222–232. [PubMed] [Google Scholar]

25. Kay SR, Abraham F, Opler LA. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophrenia Bulletin. 1987;13:261–276. [PubMed] [Google Scholar]

26. Strauss GP, Gold JM. A psychometric comparison of the clinical assessment interview for negative symptoms and the brief negative symptom scale. Schizophr Bull. 2016;42:1384–1394. [PMC free article] [PubMed] [Google Scholar]

27. Kring AM, Raquel, Steven P. The clinical assessment interview for negative symptoms (CAINS): Final development and validation. Am J Psychiatry. 2013:165–172. [PMC free article] [PubMed] [Google Scholar]

28. Velligan DI, Robertt D, Brown M. A randomized pilot study of motivation and enhancement training (MOVE) for negative symptoms. Schizophr Res. 2015;165:175–180. [PMC free article] [PubMed] [Google Scholar]

29. Daniel DG, Alphs L, Cazorla P. Training for assessment of negative symptoms of schizophrenia across languages and cultures: Comparison of the NSA-16 with the PANSS negative subscale and negative symptom factor. Clin Schizophr Relat Psychoses. 2011;5:87–94. [PubMed] [Google Scholar]

30. Daniel DG. Issues in selection of instruments to measure negative symptoms. Schizophr Res. 2013;150:343–345. [PubMed] [Google Scholar]

31. Kay SR, Abraham F, Opler LA. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull. 1987;13:261–276. [PubMed] [Google Scholar]

32. Andreasen NC. Scale for the assessment of positive symptoms (SAPS) Iowa City: University of Iowa; 1984. [Google Scholar]

33. Andreasen NC (2013) Department of psychiatry, University of Iowa college of medicine 52242.

34. Andreasen NC. Scale for the assessment of negative symptoms (SANS) Iowa City: University of Iowa; 1984. [Google Scholar]

35. Kring AM, Gur RE, Blanchard JJ, Horan WP, Reise SP. The clinical assessment interview for negative symptoms (CAINS): Final development and validation. Am J Psychiatry. 2013;170:165–172. [PMC free article] [PubMed] [Google Scholar]

36. Kirkpatrick B, Strauss GP, Nguyen L, Fischer BA, Daniel DG, et al. The brief negative symptom scale: Psychometric properties. Schizophr Bull. 2011;37:300–305. [PMC free article] [PubMed] [Google Scholar]

37. Axelrod BN, Goldman RS, Alphs LD. Validation of the 16-item negative symptomassessment. J Psychiatr Res. 1993;27:253–258. [PubMed] [Google Scholar]

38. Velligan DI, Alphs L, Lancaster S, Morlock R, Mintz J. Association between changes on the negative symptom assessment scale (NSA-16) and measures of functional outcome in schizophrenia. Psychiatry Res. 2009;169:97–100. [PubMed] [Google Scholar]

39. Portilla MPG, Alvarez LG, Saiz PA, Al Halabi S, Bascaran, et al. Psychometric evaluation of the negative syndrome of schizophrenia. Eur Arch Psychiatry Clin Neurosci. 2015;265:559–566. [PubMed] [Google Scholar]

40. Alphs L, Morlock R, Coon C, van Willigenburg A, Panagides J. The 4-item negative symptom assessment (NSA-4) instrument: A simple tool for evaluating negative symptoms in schizophrenia following brief training. Psychiatry (Edgemont) 2010;7:26–32. [PMC free article] [PubMed] [Google Scholar]

41. Alphs L, Morlock R, Coon C, Cazorla P, Szegedi A. Validation of a 4-item Negative Symptom Assessment (NSA-4): A short, practical clinical tool for the assessment of negative symptoms in schizophrenia. International Journal of Methods in Psychiatric Research 2011 [PMC free article] [PubMed] [Google Scholar]

42. Guy W. Clinical global impression In: ECDEU Assessment Manual for Psychopharmacology (revised) Rockville, MD: National Institute of Mental Health; 1976. pp. 217–221. [Google Scholar]

43. Spearing MK, Post RM, Leverich GS, Brandt D, Nolen W. Modification of the clinical global impression (CGI) scale for use in bipolar illness: The CGI-BP. Psychiatry Res. 1997;73:159–171. [PubMed] [Google Scholar]

44. Haro JM, Kamath SA, Ochoa S. The clinical global impression-Schizophrenia scale: A simple instrument to measure the diversity of symptoms present in schizophrenia. Acta Psychiatr Scand. 2003;107:16–23. [PubMed] [Google Scholar]

45. Kay SRF, Opler LA. The positive and negative syndrome Abraham scale (PANSS) for schizophrenia. Schizophrenia Bulletin. 1987;13:261–276. [PubMed] [Google Scholar]